Cover Image
市場調查報告書

中國的Ambroxol市場分析

Investigation Report on China Ambroxol Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334087
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Ambroxol市場分析 Investigation Report on China Ambroxol Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 40 Pages
簡介

Ambroxol自打入中國市場以後便急速成長。年度銷售額從2015年的2億人民幣,到2014年達成9億4,300萬人民幣,達到了年複合成長率率20.9%的成長。

本報告提供中國的Ambroxol市場相關調查分析,提供您市場規模,競爭情形,各企業的零售價格,市場預測等相關的系統性資訊。

第1章 Ambroxol的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Ambroxol的市場簡介

  • 中國的Ambroxol的專利·核準情況
  • 主要製造商
  • 市場規模

第3章 中國的Ambroxol銷售分析

  • 銷售額
  • 銷售額數量

第4章 中國的Ambroxol主要廠商的市場佔有率分析

  • 市場佔有率:不同銷售額
  • 市場佔有率:銷售額各數量

第5章 中國的Ambroxol的各劑型分析

  • 市場佔有率 (各劑型) :不同銷售額
  • 市場佔有率 (各劑型) :銷售額各數量

第6章 中國的Ambroxol的醫院用標準價格

第7章 中國市場的Ambroxol的主要製造商

  • TIPR Pharmaceutical Responsible Co., Ltd
  • Shenya Xin Ma Pharmaceutical Co., Ltd
  • Changzhou Siyao Pharmaceuticals Co., Ltd
  • Boehringer Ingelheim
  • Boehringer Ingelheim (Shanghai)

第8章 中國的Ambroxol的市場預測

  • 市場規模的預測
  • 競爭情形的預測

圖表

目錄
Product Code: 1507248

In recent years, respiratory disease has become the third health killer with high incidence and fatality in China. Therefore, developing respiratory drugs has become an important part of pharmaceutical research. In the case of respiratory tract infection like chronic bronchitis, large amounts of sputum will be generated which can block the respiratory tract and cause cough and gasp. Sputum can even make it difficult for people to breathe or spit especially when patients are children and old people. Therefore the application of expectorant represented by mucus regulator is quite necessary.

Through years of development, ambroxol, the third generation of expectorant, has been widely applied in the clinic. The chemical composition of ambroxol is ambroxol hydrochloride which is the active metabolite of bromhexine. First developed and registered by German scholars in the late 1970s, ambroxol was marketed by Boehringer Ingelheim (Germany) under the trade name of Mucosolvan in Germany in 1981. And it has now entered many countries in the world. Compared with the former two generations of expectorant, ambroxol can provide strong dissolution of mucus. Characterized by promoting alveolar cell's intake of phosphatidylcholine and synthesis of pulmonary surfactant, reducing airway resistance, stimulating mucous gland secretion and diluting mucus so as to improve its transport and release, ambroxol is now a main species of oral expectorant in the clinic.

In 1994, ambroxol made by Boehringer Ingelheim (Germany) entered China under the trade name of Mucosolvan, followed by Ambrohexal of HEXAL. Ambroxol develops fast after entering China, annual sales value rising from less than CNY 200 million in 2005 to CNY 943 million in 2014 and CAGR during this period reaching 20.9%. Boehringer Ingelheim (Spain), Shenya Xin Ma Pharmaceutical Co., Ltd, Changzhou Siyao Pharmaceuticals Co., Ltd and Boehringer Ingelheim (Shanghai) occupy the majority of the Chinese market, among which Boehringer Ingelheim (Spain) has the largest market share of about 42% for sales value in 2014.

With the degradation of environmental pollution, the incidence of respiratory diseases is expected to keep increasing, so does the market size of ambroxol in China in the next few years.

Readers can get at least the following information from this report:

  • market size of ambroxol in China
  • competitive landscape of ambroxol in Chinese market
  • price of ambroxol made by different enterprises in China
  • market outlook of ambroxol in China

The author suggests the following groups of people purchase this report:

  • manufacturers of drugs for respiratory system
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Ambroxol

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Ambroxol in China

  • 2.1. Patent and Approval Status of Ambroxol in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Ambroxol in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Ambroxol in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Ambroxol in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Ambroxol in Chinese Hospitals in 2014

  • 6.1. Boehringer Ingelheim (Shanghai) (Trade Name: Mucosolvan)
  • 6.2. Yunnan Longhai Natural Phyto Pharmaceutical Co., Ltd
  • 6.3. Boehringer Ingelheim (Germany) (Trade Name: Mucosolvan)
  • 6.4. Boehringer Ingelheim (France) (Trade Name: Mucosolvan)
  • 6.5. Boehringer Ingelheim (Spain) (Trade Name: Mucosolvan)
  • 6.6. TIPR Pharmaceutical Responsible Co., Ltd (Trade Name: Yinuoshu)
  • 6.7. Changzhou Siyao Pharmaceuticals Co., Ltd (Trade Name: Lansu)
  • 6.8. Shenya Xin Ma Pharmaceutical Co., Ltd (Trade Name: Kaishun)

7. Major Manufacturers of Ambroxol in Chinese Market, 2010-2014

  • 7.1. TIPR Pharmaceutical Responsible Co., Ltd
  • 7.2. Shenya Xin Ma Pharmaceutical Co., Ltd
  • 7.3. Changzhou Siyao Pharmaceuticals Co., Ltd
  • 7.4. Boehringer Ingelheim
  • 7.5. Boehringer Ingelheim (Shanghai)

8. Market Outlook of Ambroxol in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape
Back to Top